Receipt Bank has purchased Xavier Analytics, a portfolio company of SETsquared Bristol.
The Salesforce-backed banking platform developer has filed for a $100m initial public offering having raised $80m late last year.
The IoT security technology provider had raised $48m in funding from investors including Qualcomm and Čez pre-acquisition.
The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.
Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.
Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.
The Fosun-backed smart apparel technology provider has filed to raise just over $50m on the Shenzhen Stock Exchange’s ChiNext market.
Samsung Catalyst Fund, BMW i Ventures and NavInfo all exited street-level image repository Mapillary in an acquisition by Facebook.
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
